TRADITIONS COME WITH TIME, BUT TIMES ARE CHANGING
For the last 3 years, the GOLD report has recommended starting symptomatic patients on a LAMA/LABA.
Start Breaking Tradition
ANORO can play an important role in maximizing bronchodilation.
GO AHEAD. GET STARTED.
For patients whose COPD is not controlled by a LAMA/LABA, GOLD recommends triple therapy.
ANORO is for the once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
ANORO is NOT for the relief of acute bronchospasm or for asthma.
Start with ANORO for your symptomatic patients with COPD
Hypothetical patient story.
Frank, age 58, professor, is a symptomatic patient with moderate COPD not yet on maintenance therapy and has had no exacerbations in the last 12 months. He is currently experiencing:
- Shortness of breath leading to:
— Regular rescue medication use
— Pulling away from normal activities
ANORO is not indicated to reduce COPD exacerbations.
In GSK pivotal studies for ANORO, an exacerbation was defined as acute worsening of symptoms of COPD requiring the use of any treatment beyond study drug or rescue albuterol, including2:
- Use of antibiotics and/or systemic corticosteroids and/or
- Emergency treatment or hospitalization